1. Clinical Overview
Midazolam is a short-acting benzodiazepine central nervous system depressant. It is a water-soluble imidazobenzodiazepine available as an injectable solution (1mg/ml). In the Indian context, it is a critical drug for procedural sedation, premedication, and induction of anesthesia, valued for its rapid onset, short duration, and amnestic properties. It is a Schedule H1 drug under the Drugs and Cosmetics Rules, 1945, requiring strict prescription monitoring.
| Onset | Duration | Bioavailability |
|---|---|---|
| Intravenous: 1-5 minutes; Intramuscular: 15 minutes; Oral: 10-30 minutes. | Intravenous: 30-80 minutes; Intramuscular: 1-6 hours (dose-dependent). | Intravenous: 100%; Intramuscular: >90%; Oral/Rectal: Approximately 40-50% due to significant first-pass metabolism. |
2. Mechanism of Action
Midazolam potentiates the effects of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system. It binds to a specific site (the benzodiazepine site) on the GABA-A receptor complex, a ligand-gated chloride channel. This binding increases the frequency of chloride channel opening in response to GABA, leading to hyperpolarization of the neuronal membrane and reduced neuronal excitability.
3. Indications & Uses
- Preoperative sedation, anxiolysis, and amnesia (premedication)
- Conscious sedation before short diagnostic or endoscopic procedures
- Induction of general anesthesia (before other anesthetic agents)
- Sedation for mechanically ventilated patients in critical care settings (ICU)
4. Dosage & Administration
Adult Dosage: IM (Premedication): 0.07-0.08 mg/kg 30-60 min pre-op (usual 5 mg). IV (Sedation): Initial 0.5-2 mg slow IV over 2 min, titrate to effect; typical total 2.5-5 mg. IV (Induction): 0.15-0.3 mg/kg (unpremedicated) or 0.05-0.15 mg/kg (premedicated). ICU Infusion: Load 0.01-0.05 mg/kg, then 0.02-0.1 mg/kg/hr, titrated.
Administration: For IV: Administer slowly over at least 2 minutes; can dilute with 0.9% NaCl or 5% Dextrose. Monitor for apnea, hypotension, and oxygen saturation. Resuscitation equipment and flumazenil must be immediately available. For IM: Inject deep into a large muscle mass. Do not mix with other drugs in same syringe. Compatible with morphine, fentanyl, atropine in same IV line.
5. Side Effects
Common side effects may include:
- Respiratory depression (dose-related)
- Hypotension (especially with opioids or rapid injection)
- Sedation, drowsiness, confusion
- Injection site pain, redness, or thrombophlebitis (IV)
- Nausea, vomiting
- Hiccups
- Paradoxical reactions (agitation, restlessness, aggression - more common in children/elderly)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Opioids (Fentanyl, Morphine) | Profound additive CNS/respiratory depression, hypotension, sedation. | Major |
| Other CNS Depressants (Alcohol, Barbiturates, Propofol) | Increased sedative and respiratory depressant effects. | Major |
| CYP3A4 Inhibitors (Erythromycin, Clarithromycin, Ketoconazole, Itraconazole, Ritonavir, Grapefruit juice) | Markedly increased midazolam plasma levels, prolonged effect, risk of overdose. | Major |
| CYP3A4 Inducers (Rifampicin, Carbamazepine, Phenytoin, St. John's Wort) | Decreased midazolam plasma levels, reduced efficacy. | Moderate |
| Diltiazem, Verapamil | Increased midazolam concentration and sedation. | Moderate |
| Theophylline | May antagonize sedative effects of midazolam. | Moderate |
| Clozapine | Increased risk of cardiorespiratory collapse. | Major |
7. Patient Counselling
- Do inform your doctor about all medications, supplements, and alcohol use.
- Do arrange for someone to drive you home after the procedure.
- Do not drive, operate machinery, or make important decisions for at least 24 hours.
- Do not consume alcohol for at least 24-48 hours after receiving midazolam.
- Do not take any other sedatives or sleeping pills without consulting your doctor.
8. Toxicology & Storage
Overdose: Manifestations include somnolence, confusion, impaired coordination, diminished reflexes, coma, hypotension, respiratory depression, apnea, and cardiac arrest.
Storage: Store at controlled room temperature (15°C to 30°C). Protect from light. Do not freeze. The solution is clear and colorless to light yellow. Discard if discolored or contains particulate matter. Keep out of reach of children. For institutional use only.